

RealRate

PHARMACEUTICAL 2017

ENDOCYTE INC Rank 19 of 292







PHARMACEUTICAL 2017

ENDOCYTE INC Rank 19 of 292

The relative strengths and weaknesses of ENDOCYTE INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDOCYTE INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of ENDOCYTE INC is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 253% points above the market average of 2.9%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 140,256 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 5,562 |
| Liabilities, Non-Current | 2.9 |
| Other Assets | 34 |
| Other Compr. Net Income | 38 |
| Other Expenses | 0 |
| Other Liabilities | 782 |
| Other Net Income | 903 |
| Other Revenues | 0 |
| Property and Equipment | 3,205 |
| Research and Development | 27,492 |
| Selling, General and Administrative Expense | 17,298 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 143,494 |
| Liabilities | 6,347 |
| Expenses | 44,790 |
| Revenues | 0 |
| Stockholders Equity | 137,147 |
| Net Income | -43,888 |
| Comprehensive Net Income | -43,868 |
| Economic Capital Ratio | 256% |

